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Ulinastatin administration is associated with
a lower incidence of acute kidney injury
after cardiac surgery: a propensity score
matched study
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Abstract
Background: Systemic inflammation is involved in the development of acute kidney injury (AKI) after cardiac
surgery with cardiopulmonary bypass (CPB). Ulinastatin, a urinary trypsin inhibitor (UTI), possesses a variety of anti-
inflammatory effects. Therefore, we hypothesized that the administration of ulinastatin would reduce the occurrence of
AKI in patients undergoing cardiac surgery with CPB.
Methods: A retrospective propensity score matched analysis was used to evaluate the effect of ulinastatin on the
development of AKI in patients undergoing first documented cardiac surgery with CPB between January 2008 and
December 2012 in our hospital. Multiple logistic regression models were also employed to identify the association
between UTI administration and development of AKI.
Results: A total of 2072 patients who underwent cardiac surgery with CPB met the inclusion criteria. Before propensity
score matching, variables such as age, baseline creatinine, CPB duration, red blood cells transfused, and hematocrit
were statistically different between the ulinastatin (UTI) group and the control group. On the basis of propensity scores,
409 UTI patients were successfully matched to the 409 patients from among those 1663 patients without UTI
administration. After propensity score matching, no statistically significant differences in the baseline characteristics
were found between the UTI group and the control group. The propensity score matched cohort analysis revealed
that AKI and the need for renal replacement therapy occurred more frequently in the control group than in the UTI
group (40.83 % vs. 30.32 %, P = 0.002; 2.44 % vs. 0.49 %, P = 0.02, respectively). However, there were no significant
differences in mortality, length of intensive care unit stay, and length of hospital stay between the UTI group and the
control group. Using multivariate logistic regression analysis, we found ulinastatin played a protective role in the
development of AKI after cardiac surgery (odds ratio 0.71, 95 % confidence interval 0.56–0.90, P = 0.005).
Conclusions: This study shows that ulinastatin was associated with a lower incidence of AKI after cardiac surgery,
suggesting that the administration of ulinastatin may be favorable for those patients undergoing cardiac surgery
with CPB.
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Background
Acute kidney injury (AKI) commonly occurs in patients
undergoing cardiac surgery, especially those treated with
cardiopulmonary bypass (CPB) [1]. The incidence of car-
diac surgery–associated (CSA) AKI ranges from 8.9 %
[2] to 39 % [3], depending on the definition used. Renal
replacement therapy (RRT) is needed in 1–5 % of pa-
tients [4], and the mortality rate is 1.4 % [5]. Previous
studies demonstrated that even mild elevation in serum
creatinine (SCr) levels after cardiac surgery is signifi-
cantly associated with higher mortality [6–8]. However,
the treatment for CSA-AKI still remains challenging [9];
thus, prevention is the mainstay of effective treatment
for patients at high risk of developing AKI.
There are multiple factors involved in the development
of CSA-AKI, including hemodynamic, inflammatory,
metabolic, and nephrotoxic factors [10]. Emerging evi-
dence shows that systemic inflammation plays a key role
in the development of CSA-AKI and participates in renal
injury, especially tubular lesions [11–15].
To date, pharmacological renal protection strategies
remain limited [16]. Ulinastatin, a urinary trypsin inhibi-
tor (UTI) that inhibits various inflammatory proteases,
including chymotrypsin, trypsin, and neutrophil elastase,
has been widely used in China, Japan, and Korea for the
treatment of patients with inflammatory disorders, post-
operative organs protection, shock, and pancreatitis
[17–19]. A previous study has shown that ulinastatin can
decrease cytokine concentrations in patients undergoing
cardiac surgery [20].
However, studies investigating its renoprotective role
in the development of AKI in patients undergoing car-
diac surgery with CPB are limited [21]. Thus, the aim of
the present study was to test the hypothesis that the ad-




This retrospective study included patients aged 18 years
or older who underwent cardiac procedures with CPB at
the Nanjing First Hospital in Nanjing, China, between
January 2008 and December 2012. A total of 2072 patients
were selected for analysis. Patients with end-stage kidney
disease needing RRT before surgery were excluded.
This study was performed in accordance with the
Declaration of Helsinki and was approved by the Re-
gional Human Research Ethics Committee of Nanjing
First Hospital (reference 201409–1). Individual patient
consent was waived on condition that all patient data
were deidentified before analysis, because this study was
a retrospective analysis. The most recent examined SCr
value within 7 days before surgery was defined as the
baseline creatinine level.
Anesthesia
Patients were premedicated with intramuscular mor-
phine 0.2 mg/kg and scopolamine 0.3 mg. Anesthesia
induction was performed with midazolam 0.2 mg/kg,
fentanyl 10 μg/kg, and vecuronium 0.15 mg/kg, and then
tracheal intubation was performed. Anesthesia was
maintained with continuous propofol (4–8 mg/kg/h) and
intermittent intravenous fentanyl, midazolam, vecuro-
nium, and inhalation of 1–2 % isoflurane. Right internal
jugular vein was cannulated for transfusion. Electrocar-
diography, central venous pressure, mean arterial pres-
sure (MAP), arterial oxygen saturation, and nasopharynx
and rectal temperature were monitored.
Ulinastatin administration
Patients who were prescribed with and without ulinasta-
tin were identified and correspondingly divided into the
UTI group and the control group. Patients in the UTI
group received a bolus dose of ulinastatin 500,000 KIU
intravenously in 50 ml of saline for 15 minutes after in-
duction of anesthesia.
Anticoagulation
The dose of unfractionated heparin via central venous
catheter used for anticoagulation during CPB was 300–
400 U/kg plus additional doses to achieve and maintain
an activated clotting time between 480 and 600 seconds.
Protamine sulfate was used to reverse heparin-induced
anticoagulation after separation from CPB.
CPB management and surgical procedures
The CPB circuit was primed with a solution containing
500 ml of crystalloid solution, 1000 ml of hydroxyethyl
starch, and 200 ml of 20 % mannitol. Management of
CPB included alpha-stat pH management, MAP in the
range of 50–80 mmHg, hematocrit of 20–25 %, and a
non-pulsatile flow rate of 2.0–2.4 L/min/m2. The surgi-
cal procedures included coronary artery bypass grafting,
mitral valve replacement, mitral and aortic valve replace-
ment, and aortic valve replacement.
Data collection
The demographic, preoperative, intraoperative, and post-
operative data were collected from an electronic medical
record database. SCr was recorded each day until the
seventh day after surgery. Urine output data were not
collected, owing to absence of these data in the records.
Outcome endpoint
The primary endpoints were set as CSA-AKI, which was
defined using Kidney Disease: Improving Global Out-
comes criteria as an increase in SCr ≥0.3 mg/dl
(≥26.5 μmol/L) within 48 h, and an increase in SCr to
≥1.5 times baseline known or presumed to have
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occurred within the prior 7 days. Overall mortality, need
for RRT, intensive care unit (ICU) length of stay, and
hospital length of stay were also recorded.
Assessment of adverse events
Adverse events associated with ulinastatin, such as nau-
sea, vomiting, leukocytopenia, hypersensitivity reactions,
and elevation of transaminase, were recorded.
Statistical methods
The data were analyzed using SPSS version 18.0 software
(SPSS, Chicago, IL, USA) and the MatchIt package in R
(version 2.8.1; http://www.r-project.org/). Continuous vari-
ables following a normal distribution were expressed as
mean ± standard deviation, and categorical variables were
expressed as percentages. An unpaired t test was employed
to compare means between two groups. The χ2 test or
Fisher’s exact test was used to compare categorical variables
between two groups of subjects. The Mann–Whitney U test
was used to compare medians. Multiple regression binary
logistic regression with the backward stepwise method was
performed to evaluate the relationship between the admin-
istration of ulinastatin and the occurrence of AKI. The sig-
nificant acceptance and removal levels for a covariate were
set at 0.05 and 0.1, respectively. Data were listed as odds ra-
tios (ORs) with 95 % confidence intervals (CIs). Adjusted
variables were age, sex, body mass index (BMI), history of
hypertension, history of diabetes, insulin-controlled dia-
betes, chronic obstructive pulmonary disease (COPD),
chronic kidney disease, cerebrovascular disease, MAP, his-
tory of coronary angiography, ejection fraction, preoperative
baseline creatinine level, hematocrit, red blood cells (RBCs)
transfused, CPB duration, body temperature (>38 °C) after
surgery within 3 days, and mechanical ventilation time.
Propensity score matching
Propensity scores for each subject were generated using
a multivariable logistic regression analysis model to
compute the probability of ulinastatin administration
based on the following covariates: age, sex, BMI, dia-
betes, insulin-controlled diabetes, hypertension, COPD,
chronic kidney disease, cerebrovascular disease, coronary
angiography, preoperative baseline creatinine level, CPB
duration, MAP, erythrocyte transfusion, ejection fraction,
history of coronary angiography, hematocrit, and mech-
anical ventilation. Propensity scores were then employed
to create 1:1 matched pairs (matching the UTI users to
non-UTI users) using a nearest neighbor matching algo-
rithm without a caliper method.
Results
Patient characteristics
A total of 2072 patients who underwent cardiac surgery
with CPB met the inclusion criteria. Characteristics of
the study subjects before and after propensity score
matching are listed in (Table 1). Age, baseline creatinine,
CPB duration, RBCs transfused, and hematocrit were
statistically different between the UTI and control
groups. On the basis of the propensity score, 409 pa-
tients who received UTI were successfully matched to
409 patients who did not have the UTI treatment (Fig. 1).
After propensity score matching, no statistically signifi-
cant baseline characteristics between the UTI group and
the control group were found.
Comparison of patient outcomes
Cohort analysis revealed that AKI and RRT occurred
more frequently in the control group (40.83 % vs. 30.32 %,
P = 0.002; 2.44 % vs. 0.49 %, P = 0.02, respectively) (Fig. 2).
No statistically significant differences in ICU length of
stay, in-hospital length of stay, and mortality were found
between the control group and the UTI group (P > 0.05)
(Table 2).
Ulinastatin administration is a protective factor in the
development of AKI
Multivariate logistic regression analysis was used to de-
termine the possible protective role of ulinastatin in the
development of AKI. The results are listed in Table 3.
Notably, the administration of ulinastatin was found to
be beneficial for protecting against CSA-AKI develop-
ment (OR 0.71, 95 % CI 0.56–0.90, P = 0.005). The inde-
pendent risk factors for CSA-AKI were as follows: male
sex (OR 1.36, 95 % CI 1.12–1.66, P = 0.002), BMI (OR
1.28, 95 % CI 1.10–1.48, P = 0.001), history of hyperten-
sion (OR 1.58, 95 % CI 1.23–1.96, P < 0.001), insulin-
dependent diabetes mellitus (OR 1.59, 95 % CI 1.07–2.35,
P = 0.021), CPB duration ≥110 minutes (OR 1.38, 95 % CI
1.13–1.68, P = 0.001), body temperature (>38 °C) after sur-
gery within 3 days (OR 1.22, 95 % CI 1.016–1.49, P =
0.044), RBC units transfused (OR 1.09, 95 % CI 1.06–1.12,
P < 0.001), and mechanical ventilation time ≥9 h (OR 1.01,
95 % CI 1.00–1.02, P = 0.007).
Assessment of adverse events
No adverse events associated with UTI were found.
Discussion
In the present study, we investigated the role of ulinastatin
in the occurrence of AKI in patients undergoing cardiac
surgery with CPB. Using a propensity score matching
method, we found that patients receiving UTI treatment
had a significantly lower incidence of AKI than those in
the control group (30.32 % vs. 40.83 %, P = 0.002). Multi-
variate logistic regression analysis also revealed that uli-
nastatin played a beneficial role in the development of
AKI. The independent risk factors found in our study, such
as history of hypertension, insulin dependent diabetes,
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mechanical ventilation, CPB duration, and erythrocyte
transfusion, were in accord with a previous study [9],
while early postoperative fever (>38 °C in the first 72 h),
which is rarely caused by an infection [22], was found for
the first time (to the best of our knowledge) to be an inde-
pendent risk factor for CSA-AKI. The underlying mechan-
ism was thought to be related to systemic inflammatory
responses, which is one of the postoperative complications
in patients undergoing cardiac surgery with CPB [23].
These findings may be of importance in light of the renal
protection in this setting due to CSA-AKI being signifi-
cantly associated with higher postoperative mortality [8].
Systemic inflammatory response syndrome caused by
cardiac surgery was found to play a central role in the
development of AKI [24, 25] by deteriorating ischemia-
reperfusion injury, resulting in tubular epithelial and
vascular endothelial injury [11]. A large randomized
clinical trial has demonstrated that patients undergoing
cardiac surgery with CPB are more likely to have CSA-
AKI than those treated with surgery using a beating-
heart (off-pump) technique [1]. The possible mechanism
Fig. 1 Flowchart showing patients included in the analysis. CPB
cardiopulmonary bypass, UTI urinary trypsin inhibitor
Fig. 2 Incidence of acute kidney injury (AKI) and AKI requiring renal
replacement therapy between the control group and urinary trypsin
inhibitor (UTI) group
Table 1 Baseline characteristics of subjects before and after propensity score matched analysis










Age, yr 56 ± 13 54 ± 14 0.008 54 ± 14 54 ± 14 0.880
Male sex, n (%) 883 (53) 234 (57) 0.135 235 (57.45) 234 (57.21) 0.944
BMI, kg/m2 23.6 ± 3.6 23.4 ± 3.6 0.315 23.5 ± 3.7 23.4 ± 3.6 0.757
History of hypertension, n (%) 581 (36) 125 (31) 0.094 119 (29.1) 125 (30.6) 0.647
History of diabetes mellitus, n (%) 175 (10.5) 40 (9.8) 0.315 44 (10.8) 40 (9.8) 0.363
Insulin-controlled diabetes, n (%) 99 (6.0) 26 (6.4) 0.563 27 (6.6) 26 (6.4) 0.887
COPD, n (%) 27 (1.6) 11 (2.7) 0.150 9 (2.2) 11 (2.7) 0.490
Chronic kidney disease, n (%) 30 (1.8) 5 (1.2) 0.414 3 (0.73) 5 (1.2) 0.722
Cerebrovascular disease, n (%) 80 (4.8) 15 (3.7) 0.322 14 (3.4) 15 (3.7) 0.850
Coronary angiography, n (%) 590 (35.5) 150 (36.7) 0.651 165 (40.3) 150 (36.7) 0.281
Ejection fraction, % 59.2 ± 8.4 59.1 ± 9.4 0.953 58.9 ± 8.7 59.1 ± 9.4 0.761
Creatinine, μmol/L 75.0 ± 33.3 82.4 ± 26.9 <0.001 82.9 ± 53.9 82.4 ± 26.9 0.889
CPB duration, min 112.9 ± 48.0 106.3 ± 42.0 0.006 103.2 ± 40.2 106.3 ± 42.0 0.285
MAP, mmHg 62.3 ± 7.3 62.1 ± 5.6 0.515 62.2 ± 7.8 62.1 ± 5.6 0.803
RBCs transfused, U 4.3 ± 4.2 5.8 ± 4.9 <0.001 5.3 ± 5.3 5.8 ± 4.9 0.241
Hematocrit, % 23.4 ± 4.6 25.0 ± 5.6 <0.001 25.1 ± 5.3 25.0 ± 5.6 0.736
Mechanical ventilation, median (range) 7.8 (5.5–10.6) 7.8 (5.9–11.2) 0.073 7.8 (5.2–11.7) 7.8 (5.9–11.2) 0.078
Abbreviations: BMI body mass index, CPB cardiopulmonary bypass, MAP mean arterial pressure, COPD chronic obstructive pulmonary disease, UTI urinary trypsin
inhibitor, RBCs red blood cells
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may be associated with systemic inflammatory response,
which occurs more frequently in patients who undergo
CPB than in those treated with off-pump surgery [26].
The pathogenesis of systemic inflammatory responses
involves multiple factors, such as surgical trauma, blood
loss, transfusion, hypothermia, activation of the immune
system, ischemia-reperfusion injury and endotoxemia
[27]. The activation of humoral and cellular cascades re-
sults in an increase of proinflammatory cytokines, and
eventually leads to cellular damage and organ injury [28].
Currently, the prophylactic pharmacologic agents aimed
at attenuating the inflammatory response mainly include
propofol, statins, and glucocorticoids [29]. The benefits of
using corticosteroid prophylaxis as an anti-inflammatory
agent in patients undergoing cardiac surgery with CPB re-
main controversial [30]. Although evidence indicates that
corticosteroids are effective in reducing the risk of atrial
fibrillation and mechanical ventilation duration [31], no
difference in major outcomes was found, such as myocar-
dial infarction, renal failure, and postoperative 30-day
mortality [32, 33].
In the clinical practical setting, steroids should be pre-
scribed cautiously for those patients with contraindica-
tions to steroids, such as peptic ulcer, diabetes mellitus,
infection, and fracture. In contrast to steroids,
ulinastatin, a powerful protease inhibitor derived from
human urine, has unique anti-inflammatory properties,
which include inhibition of neutrophil elastase and other
proteases and suppression of the production of cyto-
kines, such as interleukin (IL)-6, IL-8, and tumor necro-
sis factor-α, as well as endothelial leukocyte adhesion
molecule-1 [34–38]. The possible side effects of ulinasta-
tin, such as digestive symptoms, leukocytopenia, and
hypersensitivity reactions, have rarely been observed in
clinical studies [39–41].
On the basis of these properties of ulinastatin, it has
been used to prevent postoperative complications and
post–pump organ injury in patients undergoing cardiac
surgery with CPB [42]. Nakanishi and coworkers [43]
demonstrated that prepump administration of ulinasta-
tin can suppress the elevation of postoperative IL-6 and
IL-8 in patients undergoing coronary artery bypass graft
surgery with CPB in a prospective, randomized, double-
blind, placebo-controlled study. A meta-analysis of ran-
domized controlled trials also indicates that ulinastatin
can significantly decrease cytokine concentrations in pa-
tients undergoing cardiac surgery compared with those
who received placebo [44]. Of note, a study of 60 sub-
jects in Korea showed that ulinastatin administration
has no cardiac or renal protective effects in patients
undergoing aortic valve replacement with CPB [45]. In
the study, the sample size of 30 patients in the UTI
group and 30 patients in the control group was relatively
small. Furthermore, the observation time points were
only postoperative day 1 and day 2. The mean levels of
SCr, cystatin C, and neutrophil gelatinase-associated
lipocalin were employed to determine renal injury was
present, instead of using the generally accepted Acute
Kidney Injury Network or RIFLE (risk, injury, failure,
loss, and end-stage kidney disease) criteria, making the
study not so convincing. In addition, a letter to the edi-
tor in the same journal also raised concerns that the re-
sult should be interpreted with caution due to the
relatively small sample size and the multifactorial causes
of AKI [46].
Our data show that the administration of ulinastatin
during CPB played a protective role in reducing the risk
of AKI after cardiac surgery. Although the ICU and hos-
pital lengths of stay seemed longer and mortality in the
control group was higher, no statistically significant dif-
ferences were found between the two groups. One pos-
sible reason is that the postoperative patients admitted
to the ICU were then transferred to common wards on
the second day as routine practice, unless the patients
were in critical condition. Therefore, despite the fact that
some patients developed AKI, a minor impact on the
length of ICU stay resulted. The length of in-hospital
stay was also influenced by the policy in our hospital,
which limited the average length of hospital stay.
Table 2 Comparison of outcomes between the control group






AKI, n (%) 167 (40.83) 124 (30.32) 0.002
RRT, n (%) 10 (2.44) 2 (0.49) 0.020
Death, n (%) 11 (2.69) 4 (0.98) 0.068
Length of ICU stay, d 2.5 ± 7.1 2.0 ± 2.09 0.161
Length of in-hospital stay d 22.5 ± 10.3 21.6 ± 7.4 0.147
Abbreviations: AKI acute kidney injury, RRT renal replacement therapy, UTI
urinary trypsin inhibitor, ICU intensive care unit
Table 3 Multivariable analysis determining covariate factors
associated with AKI development
Variable Adjusted OR 95 % CI P value
Male sex 1.36 1.12–1.66 0.002
BMI 1.28 1.10–1.48 0.001
History of hypertension 1.58 1.23–1.96 <0.001
Insulin-dependent diabetes 1.59 1.07–2.35 0.021
RBCs transfused, U 1.09 1.06–1.12 <0.001
CPB duration ≥110 min 1.38 1.13–1.68 0.001
Mechanical ventilation ≥9 h 1.01 1.00–1.02 0.007
Body temperature (>38 °C)
after surgery within 3 days
1.22 1.01–1.49 0.044
Ulinastatin administration 0.71 0.56–0.90 0.005
Abbreviations: AKI acute kidney injury, OR odds ratio, CI confidence interval,
BMI body mass index, RBCs red blood cells, CPB cardiopulmonary bypass
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Another aspect is that multiple factors including all
kinds of complications, such as low cardiac output syn-
drome, bleeding, infection, and heart failure, can affect
mortality and length of hospital stay. Further prospective
randomized controlled trials with large sample sizes and
perioperative administration of ulinastatin are warranted
to confirm the protective role of ulinastatin in the devel-
opment of CSA-AKI.
Our study has notable limitations. First, our study is a
retrospective, single-center study, making it prone to
bias. Second, due to the lack of urine output values, only
creatinine was used to define AKI criteria. In addition,
determining AKI on the basis of urine output was less
than practical due to the urinary catheters’ usually being
removed about 2 days after surgery.
Conclusions
Our study shows that ulinastatin administration was as-
sociated with a lower incidence of CSA-AKI, suggesting
that the administration of ulinastatin may be favorable
for those patients undergoing cardiac surgery with CPB.
Key messages
 Our results reveal ulinastatin administration was
associated with a lower incidence of CSA-AKI using
a propensity score methodology.
 Ulinastatin administration may play a protective role
against the development of CSA-AKI in patients
undergoing cardiac surgery with CPB.
Abbreviations
AKI: acute kidney injury; BMI: body mass index; CI: confidence interval;
COPD: chronic obstructive pulmonary disease; CPB: cardiopulmonary bypass;
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